Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

EBV-Status May Predict Survival in Aggressive B-NHL in the Nasopharynx

Key clinical point: A small case series suggests Epstein Barr virus (EBV) status may be a useful prognostic marker for patients with aggressive B-cell non-Hodgkin lymphomas (B-NHL) in the nasopharynx area.

Major finding: After 2- and 5-years of follow-up, the survival rates for EBV-negative patients were 100% and 83%, respectively. Patients who were EBV-positive died within 1 year of diagnosis.

Study details: A retrospective case series of 53 patients with aggressive B-NHL, including 48 patients with diffuse large B-cell lymphoma.

Disclosures: No funding sources were reported. The authors reported having no conflicts of interest.


Chen PH et al. Ann Diagn Pathol. 2019 Aug;41:129-35.